Header Logo

ANG LI

TitleAssistant Professor
InstitutionBaylor College of Medicine
DepartmentDepartment of Medicine
AddressOne Baylor Plaza
ORCID ORCID Icon0000-0002-8455-2309 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    Northwestern University, Evanston, ILBA06/2007Biological Sciences
    Baylor College of Medicine, Houston, TXMD05/2012Medicine
    Massachusetts General Hospital, Boston, MAResidency06/2015Internal Medicine
    University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WAFellowship06/2018Hematology & Oncology
    University of Washington, Seattle, WAMS03/2019Epidemiology
    Collapse awards and honors
    2007Phi Beta Kappa Honor Society Centennial Prize
    2007Fulbright Research Scholar in Science and Public Health in Spain
    2012Gold Humanism Honor Society (GHHS)
    2012Alpha Omega Alpha (AOA) Honor Society
    2014ASH Hematology Opportunities for Next Generation of Research Scientists (HONORS) Award
    2017ASH Clinical Research Training Institute (CRTI)
    2018American Society of Hematology (ASH) Abstract Achievement Award
    2019Hemostasis & Thrombosis Research Society (HTRS) Abstract Achievement Award
    2019UW Department of Medicine Chair of Medicine Scholars Award
    2020ClinGen Variant Curation Expert Panel (VCEP) Member
    2020Research and Practice in Thrombosis and Haemostasis (RPTH) Editorial Board Member
    2022Hematology the ASH Education Program Special Section Editor

    Collapse Overview 
    Collapse overview
    Dr. Li is a non-malignant hematologist who specializes in the care of patients with congenital and acquired coagulation disorders. He is a physician scientist who focuses on the prevention and treatment of venous thromboembolism (VTE) and thrombotic microangiopathy (TMA) in cancer patients receiving systemic therapy or undergoing hematopoietic cell transplantation (HCT). He is experienced in conducting clinical epidemiology and health services research using "big data", ranging from administrative claims database from public and private payers, to electronic health records (EHR) from multiple US hospital systems. He has achieved linkage of clinical/research data among the hospital/regional cancer registry, EHR data warehouse, biobanking repository, and GWAS databases. Dr. Li's group collaborates extensively with researchers in the fields of clinical epidemiology, health economics, clinical informatics, statistical genetics, and translational science, with an ultimate goal to optimally utilize big data arising from EHR toward risk factor/outcome association and prediction for cancer patients in the longitudinal setting.

    Collapse Research 
    Collapse research activities and funding
    OT2OD032581     (Bo Peng)Sep 8, 2025 - Sep 7, 2027
    NIH/ AIM-AHEAD
    Establishing Federated Learning Infrastructure for AI/ML Research on EHR Data at BCM
    Role Description: The goals are to participate and contribute data in a federated learning network created by AIM-AHEAD to improve secure data access and data sharing across various academic institutions.
    Role: Co-investigator
    R01 HL180402     (Ang Li)Aug 22, 2025 - May 30, 2030
    NIH National Heart, Lung, and Blood Institute (NHLBI)
    Multi-modal dynamic risk prediction of thrombosis and bleeding in patients with cancer
    Role Description: The goals are to develop and validate dynamic, multimodal risk prediction models for thrombosis and clinically relevant bleeding in ~330,000 cancer patients across three diverse U.S. healthcare systems using advanced methods like NLP, large language models, federated learning, and longitudinal data analysis.
    Role: PI
    U24HL176626     (GLYNN, ROBERT J)Aug 1, 2025 - Jul 31, 2032
    NIH
    (2/2) Statins to Prevent Cancer Associated Venous Thromboembolism (STAT-CAT): DCC
    Role Description: The goals are to conduct a randomized controlled trial of rosuvastatin vs placebo for the prevention of cancer associated thrombosis in intermediate-to-high risk patients when stratified by previously validated VTE risk score.
    Role: Co-Investigator
    ASH Scholar Award in Clinical Research     (Ang Li)Jul 1, 2024 - Jun 30, 2027
    American Society of Hematology
    Assessing Bleeding and Thrombosis Risk in People with Cancer using Clinical Informatics
    Role Description: The major goals are to create a validated phenotype for clinically relevant bleeding using natural language processing incorporating large language models, and to derive an optimal risk prediction model for bleeding using available clinical and biomarker data.
    Role: PI
    Conquer Cancer Career Development Award     (Ang Li)Jul 1, 2024 - Jun 30, 2027
    Conquer Cancer Foundation (CCF) of the American Society of Clinical Oncology (ASCO)
    Implementation of a patient-centered clinical decision support tool in a safety-net cancer center
    Role Description: The major goals are to create and test a clinical decision support (CDS) tool to mimic clinical trial enrollment and prevention of thromboembolic outcomes at a county hospital oncology clinic.
    Role: Principal Investigator
    3OT2OD032581-01S1 (RF00280-SUB00302)     (Vishwanatha, Jamboor)Sep 17, 2023 - Sep 16, 2025
    NIH/AIM-AHEAD
    Utilizing ethical artificial intelligence/machine learning (AI/ML) to assess and address disparity in underserved cancer patients across multiple healthcare systems with diverse social determinants of health
    Role Description: The major goals are to develop AI tools incorporating both ML-based natural language processing (NLP) and rule-based algorithms to create validated computable phenotypes for real-world data in heterogenous cancer patients enriched for racial/ethnic minorities, build optimized clinical risk prediction models for heterogeneous cancer patients that follow algorithmic fairness principles to create actionable knowledge, and test patient centered clinical decision support (PC-CDS) EHR tools.
    Role: Site MPI
    3OT2-OD032581 01S1 (RF00280-SUB00152)     (Vishwanatha, Jamboor)Sep 17, 2022 - Sep 16, 2023
    NIH/AIM-AHEAD
    Building AI/ML algorithm to predict and prevent cancer treatment complications in underserved and minority patients in a metropolitan catchment area
    Role Description: The goal of this study is to use a cancer registry-linked electronic health record (EHR) database to test AI/ML algorithms in predicting cancer therapy related complications in ~18,000 underserved and minority patients with newly diagnosed cancer.
    Role: Site MPI
    K23HL159271     (Ang Li)Apr 1, 2022 - Mar 31, 2027
    NIH/NHLBI
    Epidemiology and Biomarkers in Transplant Associated Thrombotic Microangiopathy (TA-TMA): A Prospective Validation Cohort Study
    Role Description: The goals are to prospectively assess the incidence of TA-TMA in a large pediatric cohort and to test a dynamic risk prediction tool that incorporates validated clinical and laboratory biomarkers in immune, endothelial, and complement activation pathways.
    Role: PI
    6NU38OT000280-03-02     (Neil Zakai)Sep 1, 2020 - Jul 31, 2022
    CDC
    Understanding risk factors and burden of COVID-19 related thrombosis and bleeding complications
    Role Description: The goals are to determine the incidence of thrombosis and bleeding and to assess benefit/harm of therapeutic anticoagulation among hospitalized patients with COVID-19 across 9 different hospital systems with over 10,000 patients.
    Role: Site PI
    RR190104     (Ang Li)Aug 31, 2019 - Aug 30, 2024
    Cancer Prevention & Research Institute of Texas (CPRIT)
    Role Description: The goal of this project is to study the epidemiology and prevention of cancer-associated thrombosis and to determine the patient and societal impact of a thromboprophylaxis program.
    Role: PI
    Mentored Research Award     (Ang Li)Jan 1, 2019 - Dec 31, 2020
    Hemostasis and Thrombosis Research Society (HTRS)
    Role Description: The goal of this project is to study the incidence and risk factors for patients with transplant-associated thrombotic microangiopathy using the institutional database.
    Role: PI
    NHF-Shire Clinical Fellowship     (Ang Li)Jan 1, 2019 - Dec 31, 2019
    National Hemophilia Foundation (NHF)
    Role Description: The goal of this grant is to support the dedicated clinical and research training in thrombosis and hemostasis.
    Young Investigator Award     (Ang Li)Jan 1, 2019 - Dec 31, 2019
    Conquer Cancer Foundation (CCF)
    Role Description: The goal of this project is to study the incidence of and risk factors for venous thromboembolism in high-risk multiple myeloma patients by using the SEER-Medicare database.
    Role: PI
    T32HL007093     (ABKOWITZ, JANIS L)Jul 1, 1975 - Jun 30, 2020
    NIH
    HEMATOLOGY TRAINING
    Role: Research Fellow

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Pishko AM, Li A, Cuker A. Immune Thrombotic Thrombocytopenic Purpura: A Review. JAMA. 2025 08 12; 334(6):517-529. PMID: 40388146.
      Citations: 3     Fields:    Translation:Humans
    2. Jafari O, Ma S, Lam BD, Jiang JY, Zhou E, Ranjan M, Ryu J, Bandyo R, Maghsoudi A, Peng B, Amos CI, Oluyomi A, Fillmore NR, La J, Li A, Jafari O, Ma S, Lam BD, Jiang JY, Zhou E, Ranjan M, Ryu J, Bandyo R, Maghsoudi A, Peng B, Amos CI, Oluyomi A, Fillmore NR, La J, Li A. Development and validation of venous thromboembolism-bidirectional encoder representations from transformers (VTE-BERT) natural language processing model. J Thromb Haemost. 2025 Aug 05. PMID: 40754035; PMCID: PMC12360494.
      Citations:    Fields:    
    3. Were MC, Li A, Malin BA, Yin Z, Coco JR, Collins BX, Clayton EW, Novak LL, Hendricks-Sturrup R, Oluyomi AO, Anders S, Yan C. Role and Use of Race in Artificial Intelligence and Machine Learning Models Related to Health. J Med Internet Res. 2025 Jul 31; 27:e73996. PMID: 40744520; PMCID: PMC12327910.
      Citations: 1     Fields:    Translation:Humans
    4. Zakai NA, Wilkinson K, Sparks AD, Packer RT, Roetker NS, Repp AB, Gergi M, Holmes C, Cushman M, Plante TB, Al-Samkari H, Pishko AM, Wood WA, Masias C, Gangaraju R, Li A, Garcia D, Wiggins KL, Schaefer JK, Smith NL, Ferraris A, Martin KA, Terrell DR, McClure LA. Development and validation of risk models for hospital-acquired bleeding in medical inpatients: the Medical Inpatients Thrombosis and Hemostasis (MITH) study. J Thromb Haemost. 2026 Feb; 24(2):418-430. PMID: 40683552; PMCID: PMC12329860.
      Citations:    Fields:    
    5. LI A, Zhou E. Trends and updates on the epidemiology of cancer-associated thrombosis: a systematic review. Bleeding, Thrombosis and Vascular Biology. 2025; 3(s1):108. View Publication.
    6. Lam BD, Ma S, Kovalenko I, Wang P, Jafari O, LI A, Horng S. Using a transformer language model to curate a pulmonary embolism dataset from the Medical Information Mart for Intensive Care IV: MIMIC-IV-Ext-PE. Res Pract Thromb Haemost. 2025; 9(4):102896. View Publication.
    7. Mahajan A, Parekh A, Dodge LE, Chan A, Cermak A, Cilomar Martins de Oliveira Filho, LI A, Parks AL, Schaefer JK, Gutierrez Bernal A, Tefera L, Chaturvedi S, May JE, Lake L, Angelini DE, Patell R. Surveying patients’ experiences and perspectives on venous thromboembolism: gaps and opportunities in health delivery. Blood Vessels, Thrombosis & Hemostasis. 2025. View Publication.
    8. Jiang JY, Li A, Romero A, Flowers CR, Nze C. Impact of sociodemographic determinants on enrollment into contemporary lymphoma clinical trials: a systematic review. Oncologist. 2025 Jun 04; 30(6). PMID: 40554671; PMCID: PMC12207873.
      Citations:    Fields:    Translation:Humans
    9. Subramanian NG, Guffey D, Avery J, Garcia D, Basom R, Lee SJ, Klein K, Kebriaei P, Rondon G, Shpall E, Jin S, Young E, Rojas Hernandez CM, Li A. Clinical Factors Associated With Catheter-Related VTE in Patients Undergoing Hematopoietic Cell Transplantation: A Multi-Center Study. Am J Hematol. 2025 Aug; 100(8):1463-1466. PMID: 40377378; PMCID: PMC12234234.
      Citations:    Fields:    
    10. Strauss JD, Gilbert MR, Mehta M, Li A, Ms RZ, Bondy ML, Sulman EP, Yuan Y, Liu Y, Vera E, Wendland MM, Stieber VW, Puduvalli VK, Choi S, Martinez NL, Robins HI, Hunter GK, Lin CF, Guedes VA, Richard MA, Pugh SL, Armstrong TS, Scheurer ME, Strauss JD, Gilbert MR, Mehta M, Li A, Zhou R, Bondy ML, Sulman EP, Yuan Y, Liu Y, Vera E, Wendland MM, Stieber VW, Puduvalli VK, Choi S, Martinez NL, Robins HI, Hunter GK, Lin CF, Guedes VA, Richard MA, Pugh SL, Armstrong TS, Scheurer ME. Clinical and genetic markers of vascular toxicity in glioblastoma patients: Insights from NRG Oncology RTOG-0825. Neuro Oncol. 2025 Mar 07; 27(3):767-778. PMID: 39549280; PMCID: PMC11889712.
      Citations: 3     Fields:    Translation:Humans
    11. Lam BD, Wang P, Ma S, Jafari O, Kovalenko I, LI A. Large language models for chart review: how machine learning can accelerate hematology research. Blood Vessels, Thrombosis & Hemostasis. 2025; 2(1):100052. View Publication.
    12. Dulberger KN, La J, Li A, Lotfollahzadeh S, Jose A, Do NV, Brophy MT, Gaziano JM, Ravid K, Chitalia VC, Fillmore NR. External validation of a novel cancer-associated venous thromboembolism risk assessment score in a safety-net hospital. Res Pract Thromb Haemost. 2025 Jan; 9(1):102650. PMID: 39839661; PMCID: PMC11745955.
      Citations: 3     
    13. Repp AB, Sparks AD, Wilkinson K, Roetker NS, Schaefer JK, Li A, McClure LA, Terrell DR, Ferraris A, Adamski A, Smith NL, Zakai NA. Factors associated with venous thromboembolism pharmacoprophylaxis initiation in hospitalized medical patients: the Medical Inpatients Thrombosis and Hemostasis study. J Thromb Haemost. 2024 Dec; 22(12):3521-3531. PMID: 39260742; PMCID: PMC11608142.
      Citations:    Fields:    Translation:Humans
    14. Jiang JY, Nze C, Guffey D, Kim R, Oluyomi AO, Rosales O, Bandyo R, Miller-Chism CN, Udden MM, Mims MP, Ma H, Rivero GA, Diamond A, Teegavarapu PS, Li A, Flowers CR. Clinical outcomes of patients with newly diagnosed large B-cell lymphoma in a safety-net hospital system. Blood Neoplasia. 2024 Sep; 1(3):100020. PMID: 40453060; PMCID: PMC12082142.
      Citations:    
    15. Li S, Li A, Beckman JA, Kim C, Granich MA, Mondin J, Sabath DE, Garcia DA, Mahr C. Discordance between aPTT and anti-Xa in monitoring heparin anticoagulation in mechanical circulatory support. ESC Heart Fail. 2024 Oct; 11(5):2742-2748. PMID: 38725133; PMCID: PMC11424350.
      Citations: 2     Fields:    Translation:Humans
    16. Ma S, La J, Swinnerton KN, Guffey D, Bandyo R, De Las Pozas G, Hanzelka K, Xiao X, Rojas-Hernandez CM, Amos CI, Chitalia V, Ravid K, Merriman KW, Flowers CR, Fillmore N, Li A. Thrombosis risk prediction in lymphoma patients: A multi-institutional, retrospective model development and validation study. Am J Hematol. 2024 07; 99(7):1230-1239. PMID: 38654461; PMCID: PMC11166507.
      Citations: 4     Fields:    Translation:Humans
    17. Zakai NA, Wilkinson K, Sparks AD, Packer RT, Koh I, Roetker NS, Repp AB, Thomas R, Holmes CE, Cushman M, Plante TB, Al-Samkari H, Pishko AM, Wood WA, Masias C, Gangaraju R, Li A, Garcia D, Wiggins KL, Schaefer JK, Hooper C, Smith NL, McClure LA. Development and validation of a risk model for hospital-acquired venous thrombosis: the Medical Inpatients Thrombosis and Hemostasis study. J Thromb Haemost. 2024 02; 22(2):503-515. PMID: 37918635; PMCID: PMC10872863.
      Citations: 6     Fields:    Translation:Humans
    18. Kim RB, Li A, Park KS, Kang YS, Kim JR, Navarese EP, Gorog DA, Tantry US, Gurbel PA, Hwang JY, Kwon OY, Jeong YH. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events Comparing East?Asians With Westerners: A Meta-Analysis. JACC Asia. 2023 Dec; 3(6):846-862. PMID: 38155798; PMCID: PMC10751647.
      Citations: 8     
    19. Avery J, Guffey D, Ma S, Basom R, Lee SJ, Garcia D, Rojas Hernandez CM, Li A, Martens KL. Risks factors and outcomes for isolated catheter-related deep venous thrombosis in patients undergoing allogeneic hematopoietic stem cell transplantation. Thromb Res. 2023 09; 229:1-6. PMID: 37356171; PMCID: PMC10527315.
      Citations: 6     Fields:    Translation:Humans
    20. Martens KL, Li A, La J, May SB, Swinnerton KN, Tosi H, Elbers DC, Do NV, Brophy MT, Gaziano JM, Lotfollahzadeh S, Chitalia V, Ravid K, Fillmore NR. Epidemiology of Cancer-Associated Venous Thromboembolism in Patients With Solid and Hematologic Neoplasms in the Veterans Affairs Health Care System. JAMA Netw Open. 2023 06 01; 6(6):e2317945. PMID: 37306999; PMCID: PMC10261992.
      Citations: 17     Fields:    Translation:Humans
    21. Li A, May SB, La J, Martens KL, Amos CI, Flowers CR, Do NV, Brophy MT, Chitalia V, Ravid K, Gaziano JM, Fillmore NR. Venous thromboembolism risk in cancer patients receiving first-line immune checkpoint inhibitor versus chemotherapy. Am J Hematol. 2023 08; 98(8):1214-1222. PMID: 37161855; PMCID: PMC10569448.
      Citations: 7     Fields:    Translation:Humans
    22. Thomas RM, Wilkinson K, Koh I, Li A, Warren JSA, Roetker NS, Smith NL, Holmes CE, Plante TB, Repp AB, Cushman M, Zakai NA. Development of a computable phenotype using electronic health records for venous thromboembolism in medical inpatients: the Medical Inpatient Thrombosis and Hemostasis study. Res Pract Thromb Haemost. 2023 May; 7(4):100162. PMID: 37342252; PMCID: PMC10277582.
      Citations: 3     
    23. Dima D, Li A, Granat LM, Dhillon P, Chamseddine F, Yalamanchali A, Mirzai S, Wei W, Samaras CJ, Valent J, Anwer F, Khouri J. External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs. Br J Haematol. 2023 04; 201(2):280-284. PMID: 36604838.
      Citations: 7     Fields:    Translation:Humans
    24. Li A, Martens KL, Nguyen D, Basom R, Rondon G, Jin S, Young E, Amos CI, Lee SJ, Davis C, Garcia DA, Champlin R, Shpall E, Kebriaei P, Rojas Hernandez C. External validation of the HIGH-2-LOW model: A predictive score for venous thromboembolism after allogeneic transplant. Am J Hematol. 2022 06 01; 97(6):740-748. PMID: 35266218.
      Citations: 3     Fields:    Translation:Humans
    25. Van Benschoten V, Roy C, Gupta R, Ouellette L, Hingorani S, Li A. Incidence and Risk Factors of Transplantation-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis. Transplant Cell Ther. 2022 05; 28(5):266.e1-266.e8. PMID: 35042011.
      Citations: 10     Fields:    Translation:Humans
    26. Hong W, Li A, Liu Y, Xiao X, Christiani DC, Hung RJ, McKay J, Field J, Amos CI, Cheng C. Clonal Hematopoiesis Mutations in Patients with Lung Cancer Are Associated with Lung Cancer Risk Factors. Cancer Res. 2022 01 15; 82(2):199-209. PMID: 34815255; PMCID: PMC8815061.
      Citations: 17     Fields:    Translation:Humans
    27. Martens KL, Amos CI, Hernandez CR, Kebriaei P, da Costa WL, Basom R, Davis C, Kesten M, Carrier M, Garcia DA, Lee SJ, Li A. Impact of anticoagulation on recurrent thrombosis and bleeding after hematopoietic cell transplantation. Am J Hematol. 2021 09 01; 96(9):1137-1146. PMID: 34097772.
      Citations: 7     Fields:    Translation:HumansPHPublic Health
    28. Lindquist I, Olson SR, Li A, Al-Samkari H, Jou JH, McCarty OJT, Shatzel JJ. The efficacy and safety of thrombopoietin receptor agonists in patients with chronic liver disease undergoing elective procedures: a systematic review and meta-analysis. Platelets. 2022 Jan 02; 33(1):66-72. PMID: 33459573; PMCID: PMC8286270.
      Citations: 11     Fields:    Translation:Humans
    29. Martens KL, da Costa WL, Amos CI, Davis C, Kesten M, Lee SJ, Zakai NA, Garcia DA, Li A. HIGH-2-LOW risk model to predict venous thromboembolism in allogeneic transplant patients after platelet engraftment. Blood Adv. 2021 01 12; 5(1):167-175. PMID: 33570631; PMCID: PMC7805312.
      Citations: 8     Fields:    Translation:Humans
    30. Khaki AR, Li A, Diamantopoulos LN, Miller NJ, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin V, Park J, Alva A, Bilen MA, Stewart T, Santos V, Agarwal N, Jain J, Zakharia Y, Devitt M, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lythgoe MP, Pinato DJ, Murgic J, Joshi M, Isaacsson Velho P, Hahn N, Alonso Buznego L, Duran I, Moses M, Barata P, Galsky MD, Sonpavde G, Yu EY, Shankaran V, Lyman GH, Grivas P, Morales-Barrera R, Fr?be A. A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. Eur Urol Oncol. 2021 06; 4(3):464-472. PMID: 33423945; PMCID: PMC8169524.
      Citations: 32     Fields:    Translation:Humans
    31. Desai A, Gupta R, Advani S, Ouellette L, Kuderer NM, Lyman GH, Li A. Mortality in hospitalized patients with cancer and coronavirus disease 2019: A systematic review and meta-analysis of cohort studies. Cancer. 2021 05 01; 127(9):1459-1468. PMID: 33378122.
      Citations: 77     Fields:    Translation:HumansCellsPHPublic Health
    32. Schoen MW, Carson KR, Luo S, Gage BF, Li A, Afzal A, Sanfilippo KM. Venous thromboembolism in multiple myeloma is associated with increased mortality. Res Pract Thromb Haemost. 2020 Oct; 4(7):1203-1210. PMID: 33134785; PMCID: PMC7590313.
      Citations: 25     
    33. Epperla N, Li A, Logan B, Fretham C, Chhabra S, Aljurf M, Chee L, Copelan E, Hematti P, Lazarus HM, Litzow M, Nishihori T, Olsson RF, Prestidge T, Saber W, Wirk B, Yared JA, Loren A, Pasquini M, Freytes CO. Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy. Br J Haematol. 2020 06; 189(6):1171-1181. PMID: 32124435; PMCID: PMC7726817.
      Citations: 47     Fields:    Translation:HumansCTClinical Trials
    34. Colling M, Sun L, Upadhyay V, Ryu J, Li A, Uhl L, Kaufman RM, Stowell CP, Dzik WH, Makar RS, Bendapudi PK. Deaths and complications associated with the management of acute immune thrombotic thrombocytopenic purpura. Transfusion. 2020 04; 60(4):841-846. PMID: 32080877.
      Citations: 14     Fields:    Translation:Humans
    35. Li A, Carlson JJ, Kuderer NM, Schaefer JK, Li S, Garcia DA, Khorana AA, Carrier M, Lyman GH. Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States. Cancer. 2020 04 15; 126(8):1736-1748. PMID: 31999844.
      Citations: 18     Fields:    Translation:Humans
    36. Martens KL, Khalighi PR, Li S, White AA, Silgard E, Frieze D, Estey E, Garcia DA, Hingorani S, Li A. Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia. Leuk Res. 2020 02; 89:106298. PMID: 31945598.
      Citations: 7     Fields:    Translation:Humans
    37. Khaki AR, Li A, Diamantopoulos LN, Bilen MA, Santos V, Esther J, Morales-Barrera R, Devitt M, Nelson A, Hoimes CJ, Shreck E, Assi H, Gartrell BA, Sankin A, Rodriguez-Vida A, Lythgoe M, Pinato DJ, Drakaki A, Joshi M, Isaacsson Velho P, Hahn N, Liu S, Alonso Buznego L, Duran I, Moses M, Jain J, Murgic J, Baratam P, Barata P, Tripathi A, Zakharia Y, Galsky MD, Sonpavde G, Yu EY, Shankaran V, Lyman GH, Grivas P. Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. Cancer. 2020 03 15; 126(6):1208-1216. PMID: 31829450; PMCID: PMC7050422.
      Citations: 50     Fields:    Translation:Humans
    38. Li A, Wu Q, Warnick G, Li S, Libby EN, Garcia DA, Lyman GH. The incidence of thromboembolism for lenalidomide versus thalidomide in older patients with newly diagnosed multiple myeloma. Ann Hematol. 2020 Jan; 99(1):121-126. PMID: 31773215.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    39. Starr MC, Wightman A, Munshi R, Li A, Hingorani S. Association of Food Insecurity and Acute Health Care Utilization in Children With End-stage Kidney Disease. JAMA Pediatr. 2019 Nov 01; 173(11):1097-1099. PMID: 31498384; PMCID: PMC6735494.
      Citations: 5     Fields:    
    40. Shadman M, Gauthier J, Hay KA, Voutsinas JM, Milano F, Li A, Hirayama AV, Sorror ML, Cherian S, Chen X, Cassaday RD, Till BG, Gopal AK, Sandmaier BM, Maloney DG, Turtle CJ. Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy. Blood Adv. 2019 10 22; 3(20):3062-3069. PMID: 31648329; PMCID: PMC6849954.
      Citations: 51     Fields:    Translation:HumansCells
    41. Li A, Kuderer NM, Garcia DA, Khorana AA, Wells PS, Carrier M, Lyman GH. Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and meta-analysis. J Thromb Haemost. 2019 12; 17(12):2141-2151. PMID: 31420937.
      Citations: 19     Fields:    Translation:Humans
    42. Butt JH, Li A, Xian Y, Peterson ED, Garcia D, Torp-Pedersen C, K?ber L, Fosb?l EL. Direct oral anticoagulant- versus vitamin K antagonist-related gastrointestinal bleeding: Insights from a nationwide cohort. Am Heart J. 2019 10; 216:117-124. PMID: 31425898.
      Citations: 3     Fields:    Translation:Humans
    43. Li A, Wu Q, Luo S, Warnick GS, Zakai NA, Libby EN, Gage BF, Garcia DA, Lyman GH, Sanfilippo KM. Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple Myeloma. J Natl Compr Canc Netw. 2019 07 01; 17(7):840-847. PMID: 31319391; PMCID: PMC7808759.
      Citations: 24     Fields:    Translation:Humans
    44. Li A, Garcia DA. Review: The quality of evidence is very low for periprocedural bridging in patients receiving VKA for VTE. Ann Intern Med. 2019 06 18; 170(12):JC64. PMID: 31207617.
      Citations:    Fields:    Translation:Humans
    45. Khalighi PR, Martens KL, White AA, Li S, Silgard E, Frieze D, Garcia DA, Li A. Utilization patterns and clinical outcomes of rasburicase administration according to tumor risk stratification. J Oncol Pharm Pract. 2020 Apr; 26(3):529-535. PMID: 31167612.
      Citations:    Fields:    Translation:Humans
    46. Li A, Manohar PM, Garcia DA, Lyman GH, Steuten LM. Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States. Thromb Res. 2019 Aug; 180:37-42. PMID: 31200341; PMCID: PMC6661186.
      Citations: 4     Fields:    Translation:Humans
    47. Sun L, Mack J, Li A, Ryu J, Upadhyay VA, Uhl L, Kaufman RM, Stowell CP, Dzik WS, Makar RS, Bendapudi PK. Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura. Blood Adv. 2019 05 14; 3(9):1512-1518. PMID: 31076407; PMCID: PMC6517661.
      Citations: 5     Fields:    Translation:Humans
    48. Tuazon SA, Li A, Gooley T, Eunson TW, Maloney DG, Turtle CJ, Linenberger ML, Connelly-Smith LS. Factors affecting lymphocyte collection efficiency for the manufacture of chimeric antigen receptor T cells in adults with B-cell malignancies. Transfusion. 2019 05; 59(5):1773-1780. PMID: 30729531; PMCID: PMC6499685.
      Citations: 9     Fields:    Translation:HumansCells
    49. Li A, Wu Q, Davis C, Kirtane KS, Pham PD, Sorror ML, Lee SJ, Gopal AK, Dong JF, Garcia DA, Weiss NS, R Hingorani S. Transplant-Associated Thrombotic Microangiopathy Is a Multifactorial Disease Unresponsive to Immunosuppressant Withdrawal. Biol Blood Marrow Transplant. 2019 03; 25(3):570-576. PMID: 30940363; PMCID: PMC6450411.
      Citations: 16     Fields:    Translation:Humans
    50. Wang TF, Li A, Garcia D. Managing thrombosis in cancer patients. Res Pract Thromb Haemost. 2018 Jul; 2(3):429-438. PMID: 30046747; PMCID: PMC6046582.
      Citations: 15     
    51. Li A, Garcia DA, Lyman GH, Carrier M. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. Thromb Res. 2019 01; 173:158-163. PMID: 29506866; PMCID: PMC6119655.
      Citations: 71     Fields:    Translation:HumansPHPublic Health
    52. Li A, Khalighi PR, Wu Q, Garcia DA. External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment. J Thromb Haemost. 2018 01; 16(1):164-169. PMID: 29064619; PMCID: PMC5760324.
      Citations: 20     Fields:    Translation:Humans
    53. Li A, Bendapudi PK, Uhl L, Hamdan A, Kaufman RM, Makar RS. Clinical features and outcomes in patients with thrombotic microangiopathy not associated with severe ADAMTS13 deficiency. Transfusion. 2017 09; 57(9):2151-2158. PMID: 28635017.
      Citations: 2     Fields:    Translation:Humans
    54. Boonyawat K, Caron F, Li A, Chai-Adisaksopha C, Lim W, Iorio A, Lopes RD, Garcia D, Crowther MA. Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta-analysis. J Thromb Haemost. 2017 07; 15(7):1322-1333. PMID: 28407368.
      Citations: 19     Fields:    Translation:Humans
    55. Li A, Davis C, Wu Q, Li S, Kesten MF, Holmberg LA, Gopal AK, Garcia DA. Management of venous thromboembolism during thrombocytopenia after autologous hematopoietic cell transplantation. Blood Adv. 2017 May 09; 1(12):707-714. PMID: 29296714; PMCID: PMC5728057.
      Citations: 7     Fields:    
    56. Bendapudi PK, Hurwitz S, Fry A, Marques MB, Waldo SW, Li A, Sun L, Upadhyay V, Hamdan A, Brunner AM, Gansner JM, Viswanathan S, Kaufman RM, Uhl L, Stowell CP, Dzik WH, Makar RS. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol. 2017 Apr; 4(4):e157-e164. PMID: 28259520.
      Citations: 99     Fields:    Translation:Humans
    57. Li A, Lopes RD, Garcia DA. Use of Direct Oral Anticoagulants in Special Populations. Hematol Oncol Clin North Am. 2016 10; 30(5):1053-71. PMID: 27637307.
      Citations: 2     Fields:    Translation:Humans
    58. Li A, Makar RS, Hurwitz S, Uhl L, Kaufman RM, Stowell CP, Dzik WS, Bendapudi PK. Treatment with or without plasma exchange for patients with acquired thrombotic microangiopathy not associated with severe ADAMTS13 deficiency: a propensity score-matched study. Transfusion. 2016 08; 56(8):2069-77. PMID: 27232383.
      Citations: 9     Fields:    Translation:Humans
    59. Bendapudi PK, Li A, Hamdan A, Uhl L, Kaufman R, Stowell C, Dzik W, Makar RS. Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative. Br J Haematol. 2015 Dec; 171(5):836-44. PMID: 26314936.
      Citations: 23     Fields:    Translation:Humans
    60. Marshall A, Li A, Drucker A, Dzik W. Aminocaproic acid use in hospitalized patients with hematological malignancy: a case series. Hematol Oncol. 2016 Sep; 34(3):147-53. PMID: 25641349.
      Citations: 8     Fields:    Translation:Humans
    LI's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (172)
    Explore
    _
    Co-Authors (12)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _